SCHEMBL613639

SCHEMBL613639

CCCCNc1cc(-c2ccncc2)sc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 2/20 0.52
KDM4C Q9H3R0 2/20 0.52
PTPN1 P18031 8/20 0.44
PTPRF P10586 3/20 0.44
CDC7 O00311 2/20 0.43
DBF4 Q9UBU7 1/20 0.43
ALOX15 P16050 3/20 0.42
PTPRA P18433 2/20 0.42
ROCK2 O75116 1/20 0.42
MAP4K4 O95819 1/20 0.42
PIM1 P11309 1/20 0.42
PRKACA P17612 1/20 0.42
CDK2 P24941 1/20 0.42
GSK3B P49841 1/20 0.42
HIPK2 Q9H2X6 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
LIMK1 P53667 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL611071 0.92 KDM6B (0.50) KDM6BKDM4CPTPN1PTPRFCDC7
SCHEMBL614144 0.89 CDC7 (0.54) KDM6BKDM4CCDC7DBF4ALOX15
SCHEMBL612320 0.88 KDM4E (0.48) KDM6BKDM4C
SCHEMBL613433 0.87 PTPN1 (0.48) PTPN1PTPRFCDC7DBF4PTPRA
SCHEMBL613122 0.81 CDC7 (0.57) KDM6BKDM4CCDC7DBF4CDK2
SCHEMBL613988 0.80 KDM4E (0.50) LIMK1
SCHEMBL611492 0.80 IKBKB (0.52) PTPN1PTPRFCDC7DBF4PTPRA
SCHEMBL614118 0.79 CDC7 (0.54) KDM6BKDM4CPTPN1PTPRFCDC7
SCHEMBL612106 0.76 PTPN1 (0.48) PTPN1PTPRFCDC7DBF4PTPRA
SCHEMBL613690 0.75 CDC7 (0.59) CDC7DBF4ROCK2MAP4K4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
EP-2403857-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2012-01-11 EP disclosed
WO-2010101302-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK KDM6B 673/4885KDM4C 1474/4885PTPN1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.